Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-119736 · Präparat HOS-095005
CCR5 Antagonists Maraviroc maraviroc The recommended dose for 300 mg twice daily AUC ↓ 0.47 (0.38-0.58) maraviroc when combined Cmin ↓ 0.61 (0.53-0.71) with INTELENCE and a PI Cmax ↓ 0.40 (0.28-0.57) is 150 mg twice daily, except etravirine for fosamprenavir/ritonavir AUC ↔ 1.06 (0.99-1.14) which is not recommended Cmin ↔ 1.08 (0.98-1.19) with maraviroc. No dose Cmax ↔ 1.05 (0.95-1.17) adjustment for INTELENCE Maraviroc/darunavir/ maraviroc* is necessary. ritonavir AUC ↑ 3.10 (2.57-3.74) See also section 4.4. 150/600/100 mg twice Cmin ↑ 5.27 (4.51-6.15) daily Cmax ↑ 1.77 (1.20-2.60) * compared to maraviroc 150 mg twice daily Fusion Inhibitors Enfuvirtide etravirine* No interaction is expected for 90 mg twice daily AUC ↔a either INTELENCE or C0h ↔a enfuvirtide when Enfuvirtide concentrations not studied and no co-administered. effect is expected. * based on population pharmacokinetic analyses
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enfuvirtide (HOS-088107) maraviroc (HOS-086186) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 5f7de10e1ad12e6d75c3782c01fb322e00187a8d08dd09107368e5dfe843eeec · Zeichen 9752–11507 im Abschnitt